MX383423B - Método in vitro para el diagnóstico del síndrqme del intestino irritable y la enfermedad inflamatoria intestinal. - Google Patents

Método in vitro para el diagnóstico del síndrqme del intestino irritable y la enfermedad inflamatoria intestinal.

Info

Publication number
MX383423B
MX383423B MX2016004167A MX2016004167A MX383423B MX 383423 B MX383423 B MX 383423B MX 2016004167 A MX2016004167 A MX 2016004167A MX 2016004167 A MX2016004167 A MX 2016004167A MX 383423 B MX383423 B MX 383423B
Authority
MX
Mexico
Prior art keywords
diagnosis
vitro method
inflammatory bowel
bowel disease
bowel syndrome
Prior art date
Application number
MX2016004167A
Other languages
English (en)
Spanish (es)
Other versions
MX2016004167A (es
Inventor
Christopher Chang
Mark Pimentel
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX383423(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of MX2016004167A publication Critical patent/MX2016004167A/es
Publication of MX383423B publication Critical patent/MX383423B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2016004167A 2013-10-09 2014-10-09 Método in vitro para el diagnóstico del síndrqme del intestino irritable y la enfermedad inflamatoria intestinal. MX383423B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361888658P 2013-10-09 2013-10-09
PCT/US2014/059957 WO2015054529A1 (en) 2013-10-09 2014-10-09 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Publications (2)

Publication Number Publication Date
MX2016004167A MX2016004167A (es) 2016-06-24
MX383423B true MX383423B (es) 2025-03-14

Family

ID=52813648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004167A MX383423B (es) 2013-10-09 2014-10-09 Método in vitro para el diagnóstico del síndrqme del intestino irritable y la enfermedad inflamatoria intestinal.

Country Status (19)

Country Link
US (2) US9851361B2 (OSRAM)
EP (1) EP3054977B1 (OSRAM)
JP (1) JP6567509B2 (OSRAM)
KR (1) KR102259588B1 (OSRAM)
CN (1) CN105744956B (OSRAM)
AU (2) AU2014331841B2 (OSRAM)
BR (1) BR112016007474A2 (OSRAM)
CA (1) CA2923651C (OSRAM)
CL (1) CL2016000820A1 (OSRAM)
ES (1) ES2892905T3 (OSRAM)
IL (1) IL244971B2 (OSRAM)
MX (1) MX383423B (OSRAM)
NZ (1) NZ717633A (OSRAM)
PE (1) PE20160882A1 (OSRAM)
PL (1) PL3054977T3 (OSRAM)
PT (1) PT3054977T (OSRAM)
RU (1) RU2683781C2 (OSRAM)
SG (1) SG11201601733VA (OSRAM)
WO (1) WO2015054529A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
AU2013315981B2 (en) 2012-09-17 2019-04-18 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
PE20160882A1 (es) 2013-10-09 2016-09-14 Cedars Sinai Medical Center Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal
KR102426541B1 (ko) 2014-10-09 2022-07-29 세다르스-신나이 메디칼 센터 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템
CN106053827A (zh) * 2016-05-17 2016-10-26 上海凯璟生物科技有限公司 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法
CN105784989A (zh) * 2016-05-17 2016-07-20 上海凯璟生物科技有限公司 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法
JP7475811B2 (ja) * 2016-05-20 2024-04-30 シーダーズ―シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
KR20190111094A (ko) 2017-01-30 2019-10-01 세다르스-신나이 메디칼 센터 경피증의 진단
RU2763258C1 (ru) * 2020-07-13 2021-12-28 Евгения Николаевна Воронина Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
WO2003097854A2 (en) 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP2280285A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
PT1698698E (pt) 2003-12-05 2014-03-06 Fuso Pharmaceutical Ind Genes da toxina distensora citoletal como alvos para a deteção de bactérias campylobacter
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
PL2223121T3 (pl) 2007-12-20 2012-12-31 Index Diagnostics Ab Publ Sposób różnicowania NZJ i ZJD oraz dalsze rozróżnienie odmian NZJ
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
WO2010093776A1 (en) 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
AU2013315981B2 (en) * 2012-09-17 2019-04-18 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
PE20160882A1 (es) 2013-10-09 2016-09-14 Cedars Sinai Medical Center Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal
KR102426541B1 (ko) 2014-10-09 2022-07-29 세다르스-신나이 메디칼 센터 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템
CN106091069A (zh) 2016-06-15 2016-11-09 安徽省绿巨人环境技术有限公司 一种废水再利用装置
KR20190111094A (ko) 2017-01-30 2019-10-01 세다르스-신나이 메디칼 센터 경피증의 진단

Also Published As

Publication number Publication date
EP3054977A1 (en) 2016-08-17
PE20160882A1 (es) 2016-09-14
CN105744956A (zh) 2016-07-06
KR20160062161A (ko) 2016-06-01
RU2016116766A (ru) 2017-11-15
AU2020203468A1 (en) 2020-06-18
ES2892905T3 (es) 2022-02-07
US20170038393A1 (en) 2017-02-09
MX2016004167A (es) 2016-06-24
US9851361B2 (en) 2017-12-26
RU2683781C2 (ru) 2019-04-02
CL2016000820A1 (es) 2016-09-23
IL244971B1 (en) 2023-08-01
NZ717633A (en) 2021-07-30
WO2015054529A1 (en) 2015-04-16
EP3054977A4 (en) 2017-04-12
CA2923651A1 (en) 2015-04-16
KR102259588B1 (ko) 2021-06-02
AU2014331841A1 (en) 2016-03-24
PL3054977T3 (pl) 2021-12-20
AU2014331841B2 (en) 2020-03-12
EP3054977B1 (en) 2021-07-21
CN105744956B (zh) 2021-07-20
JP2017502253A (ja) 2017-01-19
US10352944B2 (en) 2019-07-16
IL244971B2 (en) 2023-12-01
US20180196063A1 (en) 2018-07-12
BR112016007474A2 (pt) 2017-09-12
CA2923651C (en) 2023-03-14
HK1221898A1 (zh) 2017-06-16
SG11201601733VA (en) 2016-04-28
JP6567509B2 (ja) 2019-08-28
PT3054977T (pt) 2021-10-14
IL244971A0 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
MX383423B (es) Método in vitro para el diagnóstico del síndrqme del intestino irritable y la enfermedad inflamatoria intestinal.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
CL2020002225A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal
TR201903974T4 (tr) Tasnif makinesi için otomatik kusur tanı metodu ve cihazı.
MX2016013255A (es) Metodos y composiciones para detectar proteinas mal plegadas.
BR112015010012A2 (pt) método; e sistema
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
MX2017016647A (es) Anticuerpos y fragmentos anti-vista.
MX2016002537A (es) Anticuerpos y ensayos para la detección del receptor 1 de folato.
MX387936B (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
UY36223A (es) Dispositivos para ensayos, métodos para realizar ensayos, kits para ensayos y método para fabricar dispositivos para ensayos
MX384921B (es) Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR107786A1 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
MX381200B (es) Composiciones y metodos para valorar la funcion intestinal.
EA201690151A1 (ru) Способ обнаружения инфекции h. pylori
BR112016023634A2 (pt) uso de ácido micro-ribonucleico (mirna) para diagnosticar rejeição ao transplante e tolerância da terapia de imunossupressão
MX363679B (es) Metodo para diagnosticar cancer.
CY1121790T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
ES2659184T3 (es) Moduladores del receptor MRG
BR112017009605A2 (pt) método para o diagnóstico da doença de niemann-pick usando um biomarcador
NO20151763A1 (en) Portable arrangement for automatical annulus testing